Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259022 | 0.91 | — | — | |
| SCHEMBL15259013 | 0.91 | — | — | |
| SCHEMBL15289730 | 0.89 | PDE2A (0.34) | PDE2A | |
| SCHEMBL15259016 | 0.89 | PDE2A (0.34) | PDE2A | |
| SCHEMBL18788378 | 0.89 | PDE2A (0.34) | PDE2A | |
| SCHEMBL15259009 | 0.89 | — | — | |
| SCHEMBL15259035 | 0.89 | — | — | |
| SCHEMBL15259052 | 0.89 | — | — | |
| SCHEMBL19292097 | 0.89 | PDE2A (0.33) | PDE2A | |
| SCHEMBL15259053 | 0.89 | PDE2A (0.33) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210993-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170114086-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-2834258-B1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9481704-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2013138236-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES , INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130243725-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114086-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885 |
| US-20130243725-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.